Lead Sponsor

UCB Biopharma SRL

Age

6 - 17 years

Sex

ALL

Healthy Volunteers

No

•Study participant must have a diagnosis of moderate to severe plaque psoriasis (PSO) for ≥3 months and:
•1. Body Surface Area (BSA) affected by psoriasis ≥10 %
•2. Physician's Global Assessment (PGA) score ≥3 (on a scale from 0 to 4)
•3. Psoriasis Area and Severity Index (PASI) score is ≥12 or
•4. PASI score is ≥10 and \<12 with at least one of the following:
•\>Clinically relevant facial or scalp involvement
•\>Clinically relevant genital involvement
•\>Clinically relevant palm and sole involvement
•\>Clinically relevant axillary involvement Study participants aged ≥12 years may alternatively have a diagnosis of moderate to severe mixed guttate/plaque PSO with \>50 % to \<80 % guttate lesions for ≥3 months, and must meet the same criteria listed above
•Study participant must be a candidate for systemic psoriasis therapy and/or phototherapy and/or photochemotherapy

•Study participant previously participated in this study or has previously been treated with certolizumab pegol (CZP)
•Study participant has generalized pustular or erythrodermic psoriasis (PSO)
•Study participant has guttate PSO without plaque PSO
•Study participant has had a primary failure to an anti-tumor necrosis factor agent
•Study participant has had prior exposure to \>2 biologic therapies
•Study participant has a history of severe major depression or suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has had suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the "Screening/Baseline" version of the Columbia Suicide Severity Rating Scale (CSSRS) at Screening

Related studies

NCT06591273 · Moderate to Severe Chronic Plaque Psoriasis

NCT03536884 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis

NCT03410992 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, and more

NCT03370133 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, and more

NCT03598790 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis

A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis